Stockreport

SELLAS Life Sciences Announces Positive Final Data in Triple Negative Breast Cancer Patients from Phase 2b Clinical Trial of Nelipepimut-S (NeuVax™) in Combination with Trastuzumab (Hercep...

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF Clinically and statistically significant efficacy in the triple negative breast cancer cohort with a p-value of 0.013 and a 75.2% reduction in risk of relapse or death i [Read more]